T-Cell Immune Surveillance in Allogenic Stem Cell Transplant Recipients: Are Whole Blood-Based Assays Ready to Challenge ELISPOT?

Chris D LauruschkatLukas PageSonja EtterPhilipp WeisFlorian GamonSabrina KrausHermann EinseleSebastian WursterJuergen Loeffler

Published in: Open forum infectious diseases (2020)

We compared the feasibility of 4 cytomegalovirus (CMV)- and Aspergillus-reactive T-cell immunoassay protocols in allogenic stem cell transplant recipients. While enzyme-linked immunospot performed best overall, logistically advantageous whole blood-based assays performed comparably in patients with less severe lymphocytopenia. CMV-induced interferon-gamma responses correlated strongly across all protocols and showed high concordance with serology.

Keyphrases

stem cells
high throughput
high glucose
drug induced
public health
diabetic rats
epstein barr virus
dendritic cells
cell therapy
early onset
cell wall
single cell